TEVA - Teva Pharmaceutical ...About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $6.71 | Open | $6.77 |
| Volume | 32.61M | Market Cap | 9.657B |
| Yield | Last Dividend |
| CLASS ACTION UPDATE for VNTR, TEVA and N... | 12:15 PM |
| NEW YORK, NY / ACCESSWIRE / August 20, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of t... | |
| SHAREHOLDER ALERT - Teva Pharmaceutical ... | 7:00 AM |
| NEW YORK, Aug. 20, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has ... | |
| SHAREHOLDER ALERT: TEVA EGBN CAH EVH: Th... | 6:21 AM |
| NEW YORK, Aug. 20, 2019 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following compa... | |
| INVESTIGATION ALERT: The Schall Law Firm... | 5:38 AM |
| The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Teva Pharmaceu... | |
| Teva to launch generic version of EpiPen... | 5:23 AM |
| Teva Pharmaceutical Industries Ltd said on Tuesday its generic version of Mylan's EpiPen for young children will be available in most retail pharmacie... | |
| Teva says FDA-approved generic EpiPen is... | 5:09 AM |
| Teva Pharmaceutical Industries Ltd. said Tuesday its FDA-approved generic version of the EpiPen is available in the U.S. at most retail pharmacies at... | |
| Teva Announces Availability of a Generic... | 5:00 AM |
| Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced availability of the FDA-approved generic version of EpiPen Jr®1 (epinephrine inje... | |
| Warren Buffett's Portfolio Yields a... | 3:06 AM |
| It's something Buffett didn't do in the second quarter that's so shocking. | |
| [video]Teva's Generic EpiPen Jr Is N... | 2:31 AM |
| There has been an EpiPen shortage in the U.S., Europe and Canada, thanks to manufacturing delays at Pfizer. | |
| TEVA 24 Hour Deadline Alert: Approximate... | 08/19/19 |
| NEW ORLEANS, Aug. 19, 2019 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind i... | |
| CLASS ACTION UPDATE for BUD, TEVA and VE... | 08/19/19 |
| NEW YORK, NY / ACCESSWIRE / August 19, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of t... | |
| Buy rating | 08/09/19 |
| BMO Capital maintains Market Perform rating and lowers Price Target from $11.00 to $9.00 | |
| Sell rating | 07/15/19 |
| Morgan Stanley downgrades from Equal-Weight to Underweight rating and lowers Price Target from $16.00 to $6.00 | |
| Sell rating | 06/11/19 |
| Barclays initiates coverage with Underweight rating and announces Price Target of $8.00 | |
| Strong Buy rating | 06/03/19 |
| Oppenheimer upgrades from Perform to Outperform rating and announces Price Target of $12.00 | |
| Underperform rating | 05/30/19 |
| Bank of America downgrades from Buy to Underperform rating and lowers Price Target from $19.00 to $9.00 | |
| Hold rating | 05/28/19 |
| UBS downgrades from Buy to Neutral rating and lowers Price Target from $22.00 to $12.00 | |
| Buy rating | 05/09/19 |
| Wells Fargo maintains Market Perform rating and lowers Price Target from $18.00 to $17.00 | |
| Buy rating | 04/11/19 |
| Citigroup maintains Buy rating and lowers Price Target from $27.00 to $23.00 | |
| Buy rating | 04/03/19 |
| Wells Fargo maintains Market Perform rating and lowers Price Target from $20.00 to $18.00 | |
| Buy rating | 03/28/19 |
| BMO Capital initiates coverage with Market Perform rating and announces Price Target of $18.00 | |
| Hold rating | 03/20/19 |
| SunTrust Robinson Humphrey initiates coverage with Hold rating and announces Price Target of $17.00 | |
| Buy rating | 03/07/19 |
| and announces Price Target of $22.00 | |
| Hold rating | 03/06/19 |
| Morgan Stanley downgrades from Overweight to Equal-Weight rating and announces Price Target of $17.00 | |
| Date | 2019-08-07 (BMO) | Est. (EPS/Rev.) | $0.57/ 4.25B |
| Actual (EPS/Rev.) | $0.60/ $4.34 B | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Equity and Teens | Equity and Teens | 100.00 % | Follow |
| Trading | Trading | 99.00 % | Follow |
| Swing for the fences | Gino Baldassano | 78.00 % | Follow |
| Arbitrage Trade Analytics | Royce Wells | 72.00 % | Subscribe |
| smashingdon | Paul | 70.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
